Curative therapy after Atezo-Bev for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with liver cancer who have already been treated with Atezo-Bev (a combination of atezolizumab and bevacizumab) and whose tumors have shrunk significantly. The goal is to see if further curative treatments can be used to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with liver cancer (hepatocellular carcinoma).
- You must have received Atezo-Bev as your first systemic therapy for liver cancer.
- Your tumor must have either completely disappeared or shrunk by at least 30% after Atezo-Bev treatment.
- You cannot have a rare type of liver cancer called fibrolamellar carcinoma or a mixed type.
- You cannot have received other cancer treatments at the same time as Atezo-Bev, like TACE or radiofrequency ablation, unless your tumor has already been shown to be responding.
- You may have had tumor invasion into blood vessels or spread outside the liver before starting Atezo-Bev.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
This trial studies how well atezolizumab and bevacizumab work together with radiation to treat advanced hepatocellular carcinoma (liver cancer) that has spread into the portal vein. It may help shrink or control tumors and improve outcomes, but you must meet several safety and cancer-location criteria.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.